Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html

Kurszettel

Alle Kurse

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014